Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Cocrystal Pharma (COCP)

Cocrystal Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COCP
DateTimeSourceHeadlineSymbolCompany
13/05/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
13/05/202413:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
13/05/202413:00GlobeNewswire Inc.Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
07/05/202421:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:COCPCocrystal Pharma Inc
01/05/202413:00GlobeNewswire Inc.Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaNASDAQ:COCPCocrystal Pharma Inc
28/03/202412:00GlobeNewswire Inc.Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
19/03/202412:00GlobeNewswire Inc.Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza ANASDAQ:COCPCocrystal Pharma Inc
01/03/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
08/01/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
04/01/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
04/01/202413:00GlobeNewswire Inc.Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational CandidatesNASDAQ:COCPCocrystal Pharma Inc
02/01/202414:53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COCPCocrystal Pharma Inc
21/12/202322:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
06/12/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
06/12/202313:00GlobeNewswire Inc.Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza ANASDAQ:COCPCocrystal Pharma Inc
04/12/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
29/11/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
29/11/202313:00GlobeNewswire Inc.Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
27/11/202313:00GlobeNewswire Inc.Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:COCPCocrystal Pharma Inc
13/11/202313:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
13/11/202313:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
13/11/202313:00GlobeNewswire Inc.Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
09/11/202313:00GlobeNewswire Inc.Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
31/10/202312:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
31/10/202312:00GlobeNewswire Inc.Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344NASDAQ:COCPCocrystal Pharma Inc
28/09/202313:00GlobeNewswire Inc.Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and CoronavirusNASDAQ:COCPCocrystal Pharma Inc
05/09/202313:00GlobeNewswire Inc.Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:COCPCocrystal Pharma Inc
16/08/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
14/08/202313:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
14/08/202313:00GlobeNewswire Inc.Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:COCP

Your Recent History

Delayed Upgrade Clock